Jan 24, 2017 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the For investor relations and media questions, please contact:.

Director Investor Relations & Communications. Alligator Bioscience AB. aug 2017 – feb 2021 3 år 7 månader. Lund, Sverige. NeuroVive Pharmaceutical AB-bild

NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund Tel: 046-275 62 20 (växel), Fax: 046-888 83 48 info@neurovive.se, www.neurovive.se NeuroVive Pharmaceutical AB (publ) är skyldigt att offentliggöra informationen i detta pressmeddelande enligt lagen om värdepappersmarknaden. Media- och Investor Relations-relaterade frågor hänvisas till: Christine Tadgell, Tel: +46 (0)46 275 62 21 eller ir@neurovive.com.

Neurovive pharmaceutical ab investor relations

Approval o Investor relations Investors. Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m.

NeuroVive Pharmaceutical AB engages in the research and development of pharmaceuticals that protect mitochondria from death post acute traumatic injury. The company was founded by Eskil Elmer on February 1, 2000 and is headquartered in Lund, Sweden.

Media- och Investor Relations-relaterade frågor hänvisas till: Christine Tadgell, NeuroVive, Tel: 046-275 62 21 respektive ir@neurovive.com. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund Tel: 046-275 62 20 (växel), Fax: 046-888 83 48 info@neurovive.com, www.neurovive.com Ciclosporin (CicloMulsion®) utvärderas i den pågående CiPRICS-studien för akut njurskada i samband med större kirurgiska ingrepp. NeuroVive är noterat på Nasdaq Stockholm. Media- och Investor Relations-relaterade frågor hänvisas till: Christine Tadgell, Tel: +46 (0)46 275 62 21 eller ir@neurovive.com.

NeuroVive Pharmaceutical AB (publ), läkemedelsbolaget inom mitokondriell medicin, utvecklar Media samt Investor Relations-relaterade frågor hänvisas till:

Neurovive pharmaceutical ab investor relations

For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com . Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277 or ir.usa@neurovive.com. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) Investor relations Investors.

Köp aktier i Abliva - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.
Lagersystem program

Please also use the above contact if you wish to arrange an interview with NeuroVive’s CEO, Mikael Brönnegård, or its CSO, Eskil Elmér. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Catharina Jz Johansson is Chief Financial Officer & Vice President Investor Relations at NeuroVive Pharmaceutical AB. possesses experience from work on medtech growth enterprises with multinational operations. Catharina Johansson holds a M.Sc. in Business and Economics.

Via ovanstående kontaktvägar är det även möjligt att boka en intervju med företagets VD Mikael Brönnegård. NeuroVive Pharmaceutical AB (publ) NeuroVive Pharmaceutical is a Swedish biopharmaceutical company with deep expertise in mitochondrial medicine.
Arbetskläder ica maxi

vad har hänt med erik adielsson
gronsakshallen sorunda syd
michael ljungberg brottare
sd abortfragan
louise waldenström
kontakt max tv
socionomprogrammet vidareutbildning

For investor relations and media questions, please contact: Cecilia Hofvander NeuroVive Tel: +46-(0)-46-275-62-21 [email protected] NeuroVive Pharmaceutical AB (publ)

Contacts. For Investor Relations and media questions: Laika Consulting Ingmar Rentzhog Tel: +46 (0)46 275 62 21 ir@neurovive.se It is also possible to arrange an interview with NeuroVive’s CEO NeuroVive Pharmaceutical AB has successfully completed a new share issue, bringing NeuroVive close to SEK 28.2 million before issue costs. The proceeds from the rights issue will be used primarily to accelerate clinical development activities.